About

NeuroIntact, Inc. was founded in April 2023 by Bryan Nicholson to advance precision temperature modulation for hospitalized patients. The company was built on a simple vision: deliver precise clinical efficacy while maintaining therapy tolerability.

Bryan has been in the temperature modulation field since 2011, when CR Bard acquired Medivance for $250 million. That milestone sparked a long-term commitment to improving how temperature is used in medicine. Working alongside the market leader provided firsthand insight into both clinician workflow challenges and patient tolerability limitations.

VCool™ was developed with direct feedback from world-renowned physicians in the United States and internationally. The system is designed to provide controlled core body temperature modulation in a portable, practical platform.

NeuroIntact published its first-in-human study demonstrating measurable core temperature reduction with strong tolerability. Participants remained awake and required no adjunctive pharmaceuticals, reinforcing the company's focus on precision without added systemic burden.

As a first-time CEO, Nicholson assembled an experienced board. Chairman Bill Niland, inventor of Vapotherm, brings deep expertise in nasal airway technology and startup leadership. Robert Kline, a pioneer in temperature management and inventor of market-leading cooling technology, joined to support VCool's entry into the ICU market.

Headquartered in Maryland, NeuroIntact is supported by private seed funding and non-dilutive grants from the United States Marine Corps. The company is advancing a disciplined dual-market strategy across military and commercial hospital sectors while pursuing regulatory clearance in the United States and internationally.

NeuroIntact believes temperature is a powerful physiologic tool, and it should be delivered with precision, portability, and patient-centered design.